marked.bio

IDH1 inhibitor ยท small molecule

IDH305

1 active trials, targeting IDH1. Not approved for any biomarker on marked.bio yet.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
IDH1/2 mutation 1 3 Phase 1

Sponsors

Industry sponsors leading active biomarker-selected trials of IDH305.

  1. Novartis 1

Trials

1 of 3 trials shown

  1. A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations

    Active, not recruiting Phase 1 Novartis Started 2015Primary completion 2016-12 NCT02381886

    IDH305

    Documented IDH1R132-mutant tumors

    IDH1/2 mutationAdvanced Malignancies That Harbor IDHR132 Mutations